• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:徐芝龙,陈以娜,吴梅,杜凤,马艳艳.地西他滨联合CAG方案治疗老年急性髓系白血病的临床分析[J].药学研究,2020,39(8):491-493,496[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2776次   下载 2521次 本文二维码信息
码上扫一扫!
地西他滨联合CAG方案治疗老年急性髓系白血病的临床分析
徐芝龙,陈以娜,吴梅,杜凤,马艳艳
字体:加大+|默认|缩小-
(兰陵县人民医院血液科,山东 临沂 277700)
摘要:
目的 探讨老年髓系随性白血病患者的不同治疗方式及其疗效。方法 于2018年1月开展为期1年的研究,并在研究期间随机选取我院住院治疗的白血病患者作为案例探究最佳疗法。所有患者均被确诊为髓系白血病,在确诊同时将患者纳入到试验组与常规组。常规组单纯应用CAG治疗方案(阿糖胞苷+阿克拉霉素+粒细胞集落刺激因子),试验组采用地西他滨结合CAG的治疗方案。以康复效果、不良反应以及生存质量等进行对比研究。结果 试验组疗效显著优于常规组,P<0.05;试验组不良反应发生率明显少于常规组,P<0.05;干预之前两组患者的免疫指标无明显差异,数据之间的对比无意义,P>0.05;不同方案治疗后试验组免疫指标明显高于常规组,患者免疫指标改善效果突出,适用于统计学标准,P<0.05;试验组患者的平均生存率、疾病与事件相关生存期的数据均显著优于常规组,数据之间的差异较大且有意义,P<0.05。结论 为髓系白血病患者提供CAG、地西他滨的结合方案具备显著干预效果,可以有效改善患者的临床症状并延长患者生存时间、提升生存质量,值得推广普及。
关键词:  急性髓系白血病  地西他滨  CAG方案  临床疗效
DOI:10.13506/j.cnki.jpr.2020.08.014
基金项目:
The clinical analysis of dessicabine combined with CAG in the treatment of senile acute myeloid leukemia
XU Zhilong,CHEN Yina,WU Mei,DU Feng,MA Yanyan
(Department of Hematology,People's Hospital of Lanling County,Linyi 277700,China)
Abstract:
Objective To explore the different treatment methods and curative effects of elderly patients with myelogenous leukemia.Methods A one-year study was carried out in January 2018. During the study, the leukemia patients in our hospital were randomly selected as cases to explore the best treatment. All the patients were diagnosed as myeloid leukemia. At the same time, the patients were included in the experimental group and the conventional group. The conventional group was treated with CAG alone, and the experimental group was treated with dessicabine combined with CAG. The effects of rehabilitation, adverse reactions and quality of life were compared.Results The curative effect of the experimental group was significantly better than that of the conventional group (P Standard, P<0.05;The average survival rate, disease and event-related survival data of the experimental group were significantly better than those of the conventional group, and the difference between the data was significant, P<0.05.Conclusion The combination of CAG and dessicabine for patients with myeloid leukemia has a significant intervention effect, which can effectively improve the clinical symptoms, prolong the survival time and improve the quality of life of patients. It is worth popularizing.
Key words:  Acute myeloid leukemia  Dessicabine  CAG regimen  Clinical efficacy
今日访问量:2425    总访问量:55338835
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司